WaveBreak is taking a transformative approach to drug discovery, targeting the fleeting intermediates that are central to many disease pathways but have been beyond the reach of conventional drug discovery approaches.

Our focus is on several of the most prominent unmet medical needs of our time: Neurodegeneration in Parkinson’s disease, Lewy body dementia, Alzheimer’s disease, and ALS.

Press Releases

December 6, 2024
WaveBreak Presents First Preclinical Data Demonstrating Efficacy of Small Molecule WTX-245 Inhibiting Source Mechanisms of TDP-43 Pathology, with Disease-Modifying Potential in ALS and FTD
March 8, 2024
WaveBreak Presents New Preclinical Data at AD/PD 2024 Demonstrating Efficacy of Oral Clinical Candidate WTX-607 in Preventing Formation of Toxic α-Synuclein Oligomers and Aggregates, with Disease-Modifying Potential in Parkinson’s Disease and Lewy Body Dementia
Back to Top